A new trading day began on Friday, with Arbutus Biopharma Corp (NASDAQ: ABUS) stock price down -3.96% from the previous day of trading, before settling in for the closing price of $3.03. ABUS’s price has ranged from $1.69 to $3.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 55.33% over the past five years. Meanwhile, its annual earnings per share averaged -1.36%. With a float of $136.99 million, this company’s outstanding shares have now reached $169.87 million.
Let’s look at the performance matrix of the company that is accounted for 73 employees.
Arbutus Biopharma Corp (ABUS) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Arbutus Biopharma Corp is 23.68%, while institutional ownership is 43.84%. The most recent insider transaction that took place on Feb 02 ’24, was worth 23,504. In this transaction Interim President & CEO of this company sold 10,164 shares at a rate of $2.31, taking the stock ownership to the 1,504,793 shares. Before that another transaction happened on Feb 02 ’24, when Company’s Chief Scientific Officer sold 9,982 for $2.31, making the entire transaction worth $23,083. This insider now owns 1,485,121 shares in total.
Arbutus Biopharma Corp (ABUS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.91 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.36% per share during the next fiscal year.
Arbutus Biopharma Corp (NASDAQ: ABUS) Trading Performance Indicators
Here are Arbutus Biopharma Corp’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.87. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 28.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.44, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.53 in one year’s time.
Technical Analysis of Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (NASDAQ: ABUS) saw its 5-day average volume 0.93 million, a negative change from its year-to-date volume of 1.28 million. As of the previous 9 days, the stock’s Stochastic %D was 68.01%. Additionally, its Average True Range was 0.15.
During the past 100 days, Arbutus Biopharma Corp’s (ABUS) raw stochastic average was set at 75.00%, which indicates a significant increase from 61.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.93% in the past 14 days, which was higher than the 43.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.73, while its 200-day Moving Average is $2.25. Nevertheless, the first resistance level for the watch stands at $2.99 in the near term. At $3.08, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.12. If the price goes on to break the first support level at $2.86, it is likely to go to the next support level at $2.82. The third support level lies at $2.73 if the price breaches the second support level.
Arbutus Biopharma Corp (NASDAQ: ABUS) Key Stats
With a market capitalization of 522.32 million, the company has a total of 179,492K Shares Outstanding. Currently, annual sales are 18,140 K while annual income is -72,850 K. The company’s previous quarter sales were 2,150 K while its latest quarter income was -19,310 K.
